Uncle Kory Foundation
Historical funder research: IRS Form 990-PF filings from US private foundations, showing who funded what in past years. This is not a list of currently open grant calls, and we do not track open RFPs from private foundations. From public IRS Form 990-PF filings (latest on file for this funder: tax year 2025). Coverage: tax years 2019–2025. Freshness: the IRS releases these returns 1.5–2+ years after the tax year ends, so 2025 is still partial and a funder's newest grants may not appear yet. Last updated: November 14, 2026. Filings can contain errors, so confirm current priorities and deadlines with the funder before applying.
Year 2025 is still partial because many returns have not been filed or released yet. That is a freshness issue — coverage in our dataset is tax years 2019–2025.
Only 39.2% of this funder's organizational grants could be linked to an IRS cause code.
The foundation checked the box saying it contributes only to preselected organizations and doesn't accept unsolicited requests.
- Form & materials
- Not stated
- Deadlines
- Not stated
- Restrictions
- Not stated
| Recipient | Location | Purpose (as filed) | Amount | Tax yr |
|---|---|---|---|---|
| University of Southern California | Los Angeles, CA | THE ROLE OF GABA TRANSAMINASE IN MEDULLOBLASTOMA LOCAL RECURRENCE AND ITS POTENTIAL AS A THERAPEUTIC TARGET IN MEDULLOBLASTOMA METASTASIS 3RD YEAR FUNDING | $50,000 | 2025 |
| University of California San Francisco | San Francisco, CA | DEFINING NEURAL DEPENDENT VULNERABILITIES IN GBM RADIATION SENSITIZATION USING FUNCTIONAL GENOMICS | $50,000 | 2025 |
| University of Alabama at Birmingham | Birmingham, AL | TARGETING RECURRENT GLIOBLASTOMA CELLS USING COLLAGEN-BINDING IL-12 AND IL-7 | $50,000 | 2025 |
| The University of Texas MD Anderson Cancer Center | Houston, TX | AUTOPHAGY INHIBITION TO SENSITIZE MEDULLOBLASTOMA TO ENHANCE NK CELL IMMUNOTHERAPY | $50,000 | 2025 |
| The University of Texas MD Anderson Cancer Center | Houston, TX | PROJECT FP00009152 - REPURPOSING MIGRAINE TREATMENTS FOR DIPG - 5TH YEAR FUNDING | $50,000 | 2025 |
| The Ucla Foundation | Los Angeles, CA | HAPTEN-MODIFIED NEOANTIGENS AS IMMUNE TARGETS FOR GLIOBLASTOMA TREATMENT | $50,000 | 2025 |
| Regents University of California Los Angeles | Los Angeles, CA | CHARACTERIZING PTPRZ1 MECHANISM IN CANCER AS A THERAPEUTIC TARGET, 3RD YEAR FUNDING | $50,000 | 2025 |
| Duke University | Durham, NC | SIRPIGLENASTAT FOR TREATING GLIOBLASTOMA | $50,000 | 2025 |
| Cornell University | Ithaca, NY | TO FUND PROJECT "REGULATION OF MYELOID CELLS BY FATTY ACID METABOLISM IN IRRADIATED GLIOBLASTOMA." 2ND YEAR RENEWAL | $50,000 | 2025 |
| City of Hope | Duarte, CA | TARGETING NON-CODING RNA PSEUDOURIDINE MODIFICATION FOR GLIOBLASTOMA THERAPY | $50,000 | 2025 |
| Duke University | Durham, NC | "THE CARE-BEAR PROPOSAL." 2ND YEAR RENEWAL; PORTION TRANSFERRED TO UNIVERSITY OF COLORADO. REMAINING FUNDS REIMBURSED AND THEN ALLOCATED TO UNIVERSITY OF COLORADO REGENTS. | $33,584 | 2025 |
| The Mark Foundation for Cancer Research | New York, NY | FOUNDATION GIFT FOR THE GBM INITIATIVE | $25,000 | 2025 |
| Regents of the University of Colorado | Aurora, CO | "THE CARE-BEAR PROPOSAL." 2ND YEAR RENEWAL | $16,416 | 2025 |
| Central Brain Tumor Registry of the United States | Hinsdale, IL | GENERAL SUPPORT | $5,000 | 2025 |
| Brain Tumor Epidemiology Consortium | Hinsdale, IL | CHARACTERIZING PTPRZ1 MECHANISM IN CANCER AS A THERAPEUTIC TARGET, 3RD YEAR FUNDING | $5,000 | 2025 |
| The Ucla Foundation | Los Angeles, CA | TO SUPPORT THE WORK OF DR. CLOUGHESY AND DR. LIAU AT THE BRAIN TUMOR CENTER OF UCLA. | $579 | 2025 |
| Childrens Hospital Los Angeles | Los Angeles, CA | CEREBROSPINAL FLUID LIQUID BIOPSY ON PEDIATRIC EMBRYONAL CENTRAL NERVOUS SYSTEM TUMORS. | $50,000 | 2024 |
| Duke University | Durham, NC | THE CARE-BEAR PROPOSAL. | $50,000 | 2024 |
| Regents University of California | Santa Cruz, CA | CHARACTERIZING PTPRZ1 MECHANISM IN CANCER AS A THERAPEUTIC TARGET, 2ND YEAR FUNDING | $50,000 | 2024 |
| The University of Texas MD Anderson Cancer Center | Houston, TX | TO SUPPORT PROJECT "IDENTIFICATION OF NON-CANONICAL ANTIGENS OF DEVELOPMENT OF NOVEL IMMUNOTHERAPIES IN GLIOBLASTOMA. | $50,000 | 2024 |
| City of Hope | Duarte, CA | FUNDING PROJECT ADVANCING IL13RA2-CAR T CELL THERAPY AGAINST GLIOBLASTOMA BY ENHANCING IFNSIGNALING | $50,000 | 2024 |
| Cornell University - Weill Cornell Medicine | Ithaca, NY | TO FUND PROJECT "REGULATION OF MYELOID CELLS BY FATTY ACID METABOLISM IN IRRADIATED GLIOBLASTOMA." | $50,000 | 2024 |
| University of Southern California | Los Angeles, CA | THE ROLE OF GABA TRANSAMINASE IN MEDULLOBLASTOMA LOCAL RECURRENCE AND ITS POTENTIAL AS A THERAPEUTIC TARGET IN MEDULLOBLASTOMA METASTASIS 2ND YEAR FUNDING | $50,000 | 2024 |
| The Ucla Foundation | Los Angeles, CA | TO THE NEUROSURGERY BRAIN TUMOR PROGRAM RESEARCH FUND (60358C) FOR DR. LINDA LIAU. | $37,500 | 2024 |
| The Ucla Foundation | Los Angeles, CA | FOR THE UCLA BRAIN CANCER RESEARCH GIFT FUND (61893C) LED BY DR. CLOUGHESY. | $37,500 | 2024 |
Grants to individuals are counted but not named.
The free funder search finds foundations that funded organizations like your client's, by cause and location. Free templates: multi-client grant calendar, grant tracker. GrantCorral is a workspace for grant consultants with several clients; founding members get 60 days free on Consultant, no card required, then 50% off the first year if they stay.